Digoxin Immune Fab

13-oxoODE is produced from 13-HODE by a NAD+-dependent dehydrogenase present in rat colonic mucosa. 13-OxoODE stimulates cell proliferation when instilled intrarectally in rats.

An oxygenation product of DHA that serves as a precursor to the anti-inflammatory, pro-resolving maresin 1 doses as low as 0.2 ng/mouse resulted in reduced infiltration of PMNs into sites of inflammation.

An oxygenation product of DHA that serves as a precursor to the anti-inflammatory, pro-resolving maresin 1 doses as low as 0.2 ng/mouse resulted in reduced infiltration of PMNs into sites of inflammation.

An oxygenation product of DHA that serves as a precursor to the anti-inflammatory, pro-resolving maresin 1 doses as low as 0.2 ng/mouse resulted in reduced infiltration of PMNs into sites of inflammation.

Application 7&#945:,25-Dihydroxycholesterol has been used as a ligand for G protein-coupled receptor 183 (Gpr183). Biochem/physiol Actions 7&#945:,25-Dihydroxycholesterol (7&#945:,25-OHC) is a potent and selective endogenous ligand for the

Application 7&#945:,25-Dihydroxycholesterol has been used as a ligand for G protein-coupled receptor 183 (Gpr183). Biochem/physiol Actions 7&#945:,25-Dihydroxycholesterol (7&#945:,25-OHC) is a potent and selective endogenous ligand for the

Actoxumab (anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab (anti-Cdiff Toxin A) prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile.

Actoxumab (anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab (anti-Cdiff Toxin A) prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile.

Actoxumab (anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab (anti-Cdiff Toxin A) prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile.

Actoxumab (anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab (anti-Cdiff Toxin A) prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile.

AGN194204 (IRX4204) is an orally active and selective RXR agonist with K d values 0.4 nM, 3.6 nM and 3.8 nM and EC 50 s of 0.2 nM, 0.8 nM and 0.08 nM for RXRα , RXRβ and RXRγ , respectively. AGN194204 is inactive against RAR. AGN194204 has

AGN194204 (IRX4204) is an orally active and selective RXR agonist with K d values 0.4 nM, 3.6 nM and 3.8 nM and EC 50 s of 0.2 nM, 0.8 nM and 0.08 nM for RXRα , RXRβ and RXRγ , respectively. AGN194204 is inactive against RAR. AGN194204 has